False-negative results of combined endobronchial and endoscopic ultrasound in mediastinal staging of lung cancer

肺癌纵隔分期中支气管内超声和内镜超声联合检查的假阴性结果

阅读:1

Abstract

INTRODUCTION: Accurate assessment of mediastinal lymph node involvement is crucial for treatment planning in lung cancer. Combined endobronchial and endoscopic ultrasound (CUS) offers high sensitivity and negative predictive value (NPV), but false negative (FN) results remain a concern due to their potential impact on treatment strategies. AIM: We aimed to analyze factors associated with FN CUS results in patients with lung cancer. MATERIAL AND METHODS: We conducted a retrospective analysis of a prospective database of adult patients with lung cancer clinical stage I-IVA, staged using positron emission tomography (PET), computed tomography (CT), and CUS, who underwent lung resection. The analyzed data included age, sex, body mass index (BMI), tumor histology and grade, lobar location, stage of the disease and maximum standardized uptake values (SUV(max)) of the primary tumor and lymph nodes. RESULTS: Among 775 analyzed patients, there were 86 (11%) FN results. The risk of FN CUS results was significantly associated with female sex (p = 0.014), adenocarcinoma histology (p = 0.039), higher clinical stage determined using both CT (p = 0.001-0.036) and PET (p = 0.001-0.028), higher SUV of N2 nodes (p < 0.001), and higher SUV of N1 nodes (p = 0.012). No significant association was found between the risk of FN CUS results and patients' age (p = 0.421), BMI (p = 0.921), or primary tumor characteristics, including lobar location (p = 0.29-0.99), grade (p = 0.67-0.88), and SUV(max) (p = 0.12). CONCLUSIONS: FN CUS results are more likely in women, with adenocarcinoma histology and higher clinical stage determined using CT and PET. Age, BMI, and primary tumor lobar location, grade, and SUVmax are not predictors of FN.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。